A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Key Inclusion Criteria:

• Disease Criteria: Evidence of T-ALL or T-LBL, as defined by World HealthOrganization (WHO) classification, and either relapse/refractory or MRD positive

• Age: Lower age limit of ≥ 1 year; adequate organ function

• Eastern Cooperative Oncology Group (ECOG)/Karnofsky Performance Status 0 or 1/70 andabove at Screening.

Key Exclusion Criteria:

• Prior treatment with any anti-CD7 therapy.

• Patients with decompensated hemolytic anemia.

• Presence of Grade 2 to 4 acute or extensive chronic GvHD requiring systemicimmunosuppression. Grade 1 GvHD not requiring immunosuppression or Grade 2 skin GvHDif treated with topical therapy only are acceptable.